Ting Xu1, Qing H Meng2, Susan C Gilchrist3, Steven H Lin1, Ruitao Lin4, Tianlin Xu5, Sarah A Milgrom6, Saumil J Gandhi1, Haijun Wu7, Yu Zhao8, Juan C Lopez-Mattei9, Radhe Mohan10, Zhongxing Liao11. 1. Departments of Radiation Oncology. 2. Laboratory Medicine. 3. Clinical Cancer Prevention and Cardiology. 4. Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. 6. Department of Radiation Oncology, University of Colorado-Denver, Denver, Colorado. 7. Department of Radiation Oncology, Xiangya Hospital, Xiangya Medical School of Central South University, Hunan, P. R. of China. 8. Department of Medicine, University Hospital, Rochester, New York. 9. Departments of Cardiology. 10. Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 11. Departments of Radiation Oncology. Electronic address: zliao@mdanderson.org.
Abstract
PURPOSE: Cardiotoxicities induced by cancer therapy can negatively affect quality of life and survival. We investigated whether high-sensitivity cardiac troponin T (hs-cTnT) levels could serve as biomarker for early detection of cardiac adverse events (CAEs) after chemoradiation therapy (CRT) for non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This study included 225 patients who received concurrent platinum and taxane-doublet chemotherapy with thoracic radiation therapy to a total dose of 60 to 74 Gy for NSCLC. All patients were evaluated for CAEs; 190 patients also had serial hs-cTnT measurements. RESULTS: Grade ≥3 CAEs occurred in 24 patients (11%) at a median interval of 9 months after CRT. Pretreatment hs-cTnT levels were higher in men, in patients aged ≥64 years, and in patients with pre-existing heart disease or poor performance status (P < .05). hs-cTnT levels increased at 4 weeks during CRT (P < .05) and decreased after completion of CRT but did not return to pretreatment levels (P = .002). The change (Δ) in hs-cTnT levels during CRT correlated with mean heart dose (P = .0004), the heart volumes receiving 5 to 55 Gy (P < .05), and tumor location (P = .006). Risks of severe CAEs and mortality were significantly increased if the pretreatment hs-cTnT was >10 ng/L or the Δ during CRT was ≥5 ng/L. CONCLUSIONS: Elevation of hs-cTnT during CRT was radiation heart dose-dependent, and high hs-cTnT levels during the course of CRT were associated with CAEs and mortality. Routine monitoring of hs-cTnT could identify patients who are at high risk of CRT-induced CAEs early to guide modifications of cancer therapy and possible interventions to mitigate cardiotoxicity.
PURPOSE: Cardiotoxicities induced by cancer therapy can negatively affect quality of life and survival. We investigated whether high-sensitivity cardiac troponin T (hs-cTnT) levels could serve as biomarker for early detection of cardiac adverse events (CAEs) after chemoradiation therapy (CRT) for non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: This study included 225 patients who received concurrent platinum and taxane-doublet chemotherapy with thoracic radiation therapy to a total dose of 60 to 74 Gy for NSCLC. All patients were evaluated for CAEs; 190 patients also had serial hs-cTnT measurements. RESULTS: Grade ≥3 CAEs occurred in 24 patients (11%) at a median interval of 9 months after CRT. Pretreatment hs-cTnT levels were higher in men, in patients aged ≥64 years, and in patients with pre-existing heart disease or poor performance status (P < .05). hs-cTnT levels increased at 4 weeks during CRT (P < .05) and decreased after completion of CRT but did not return to pretreatment levels (P = .002). The change (Δ) in hs-cTnT levels during CRT correlated with mean heart dose (P = .0004), the heart volumes receiving 5 to 55 Gy (P < .05), and tumor location (P = .006). Risks of severe CAEs and mortality were significantly increased if the pretreatment hs-cTnT was >10 ng/L or the Δ during CRT was ≥5 ng/L. CONCLUSIONS: Elevation of hs-cTnT during CRT was radiation heart dose-dependent, and high hs-cTnT levels during the course of CRT were associated with CAEs and mortality. Routine monitoring of hs-cTnT could identify patients who are at high risk of CRT-induced CAEs early to guide modifications of cancer therapy and possible interventions to mitigate cardiotoxicity.
Authors: Mary Feng; Jean M Moran; Todd Koelling; Aamer Chughtai; June L Chan; Laura Freedman; James A Hayman; Reshma Jagsi; Shruti Jolly; Janice Larouere; Julie Soriano; Robin Marsh; Lori J Pierce Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Katelyn M Atkins; Bhupendra Rawal; Tafadzwa L Chaunzwa; Nayan Lamba; Danielle S Bitterman; Christopher L Williams; David E Kozono; Elizabeth H Baldini; Aileen B Chen; Paul L Nguyen; Anthony V D'Amico; Anju Nohria; Udo Hoffmann; Hugo J W L Aerts; Raymond H Mak Journal: J Am Coll Cardiol Date: 2019-06-18 Impact factor: 24.094
Authors: Shaun G Goodman; Philippe Gabriel Steg; Kim A Eagle; Keith A A Fox; José López-Sendón; Gilles Montalescot; Andrzej Budaj; Brian M Kennelly; Joel M Gore; Jeanna Allegrone; Christopher B Granger; Enrique P Gurfinkel Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Am J Cardiol Date: 2011-03-02 Impact factor: 2.778
Authors: Nicholas A Serrano; Ross Mikkelsen; Justin Canada; Eleonora Mezzaroma; Elisabeth Weiss; Antonio Abbate Journal: Int J Cardiol Date: 2016-08-15 Impact factor: 4.164
Authors: M Jacob Adams; Steven E Lipshultz; Cindy Schwartz; Luis F Fajardo; Veronique Coen; Louis S Constine Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Kyle Wang; Michael J Eblan; Allison M Deal; Matthew Lipner; Timothy M Zagar; Yue Wang; Panayiotis Mavroidis; Carrie B Lee; Brian C Jensen; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks Journal: J Clin Oncol Date: 2017-01-23 Impact factor: 50.717
Authors: V De Sanctis; M Alfò; C Vitiello; G Vullo; G Facondo; L Marinelli; S Burocchi; G Gallo; M Valeriani; B Campanella; G Scalabrino; I Russo; G Salerno; P Cardelli; M F Osti; L De Biase Journal: Clin Breast Cancer Date: 2020-09-10 Impact factor: 3.225